Gurjeet Jutley1, Daniel Sibley2, Fasial Ahmed2

Purpose: ECP is a MIGS procedure that allows management of IOP at the time of cataract surgery or as an adjunct to existing therapies. We describe the longest follow up of Phaco-ECP to demonstrate its long-term efficacy.
Method: We retrospectively analysed patients undergoing Phaco-ECP over six years at a tertiary referral centre in London. 199 eyes were reviewed with follow-up of 40.4 months 21.5. The aetiology included POAG (72.3%), PXFG (11.6%) and CNAG
(6.4%). Thirty (15.1%) eyes had previous trabecu- lectomy surgery, twelve eyes (6.0%) had YAG PI’s, three eyes had SLT, one eye (0.5%) had a Baerveldt tube in situ and one eye (0.5%) previously had TSC. Results: The mean VA at baseline was 0.7 logMAR 0.8, improving annually to 0.46 logMAR 0.75 (P < 0.001) at one year and 0.24 logMAR 0.20 (P = 0.606) at six years. Twenty eyes had a decrease in vision of more than 0.2 logMAR, attributed to AION, AMD, DMO and traumatic globe perforation. The mean baseline IOP was 19.3 mmHg 6.4 and had a sustained improvement each year of fol- low up: 14.8 mmHg 5.2 (P < 0.001) at one year (represent- ing a mean reduction of 4.5 mmHg) 13.5 mmHg 1.0 (P = 0.011) at year six. Eleven patients required further filtration surgery and two eyes had repeat ECP. Conclusion: We present a heterogeneous group with multiple different diagnoses, previous proce- dures and differing stages of glaucoma, including advanced VF loss. This is the longest follow-up of such patients showing the sustained pressure lower- ing effects of phaco-ECP.